High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy

C. Mangioni, S. Franceschi, C. La Vecchia, M. D'Incalci

Research output: Contribution to journalArticlepeer-review

Abstract

Out of 33 evaluable patients with advanced ovarian cancer, resistant to extensive poly-chemotherapy, then treated with high-dose im medroxyprogesterone (MPA), five partial responses (15%) were obtained. No partial response was obtained in a comparable group of 30 patients treated with an oral schedule. Four patients (two po, 2 im) had stable disease for at least 3 months, and 16 experienced subjective improvement. Treatment was very well tolerated. This study shows that high-dose MPA has some activity in ovarian cancer, and is worthy of further investigation.

Original languageEnglish
Pages (from-to)314-318
Number of pages5
JournalGynecologic Oncology
Volume12
Issue number3
DOIs
Publication statusPublished - 1981

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint

Dive into the research topics of 'High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy'. Together they form a unique fingerprint.

Cite this